Sheng Lou1, Russell Taylor2, Sandra Pearce3, Mary Kuhns4, Thomas Leary5. 1. Diagnostics Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL,60064, USA. Electronic address: sheng.lou@abbott.com. 2. Diagnostics Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL,60064, USA. Electronic address: russell.taylor@abbott.com. 3. Diagnostics Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL,60064, USA. Electronic address: sandra.pearce@abbott.com. 4. Diagnostics Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL,60064, USA. Electronic address: mary.kuhns@abbott.com. 5. Diagnostics Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL,60064, USA. Electronic address: thomas.leary@abbott.com.
Abstract
BACKGROUND: Critical to the identification of HBV infection and the prevention of transfusion transmitted disease is the sensitive and accurate detection of Hepatitis B virus surface antigen (HBsAg). Improvements in HBsAg assay sensitivity approaching the performance of nucleic acid testing (NAT) are essential to further reduce the detection window for acute HBV infection in regions where NAT is not widely available. OBJECTIVES AND STUDY DESIGN: An improved HBsAg assay on the fully-automated Abbott ARCHITECT® platform was developed to improve sensitivity, mutant and genotype detection. RESULTS: The analytical sensitivity of the improved prototype assay is 5.2 mIU/ml, which is 3.86- to 14.54-fold more sensitive than comparator assays based on the WHO International Reference Standard. The enhanced sensitivity was also demonstrated with 27 HBV seroconversion panels, detecting more panel members (191 of 364) vs. the ARCHITECT® Qual I (144), Qual II (160) and PRISM® (148) HBsAg assays. Further, the assay detected 7 of 12 HBV DNA positive/HBsAg negative samples, and detected all evaluated mutants and genotypes with higher sensitivity than the comparator assays. The improvement in sensitivity did not diminish assay specificity, attaining 100% (95% CI, 99.97-100%) on 10,633 blood donors. CONCLUSIONS: An Abbott ARCHITECT® HBsAg assay with clinical performance approaching that of mini-pool NAT (approximately 100 copies/ml was developed. The assay has superior HBsAg mutant and genotype detection and specificity, all of which are important for the diagnosis and management of HBV infection.
BACKGROUND: Critical to the identification of HBV infection and the prevention of transfusion transmitted disease is the sensitive and accurate detection of Hepatitis B virus surface antigen (HBsAg). Improvements in HBsAg assay sensitivity approaching the performance of nucleic acid testing (NAT) are essential to further reduce the detection window for acute HBV infection in regions where NAT is not widely available. OBJECTIVES AND STUDY DESIGN: An improved HBsAg assay on the fully-automated Abbott ARCHITECT® platform was developed to improve sensitivity, mutant and genotype detection. RESULTS: The analytical sensitivity of the improved prototype assay is 5.2 mIU/ml, which is 3.86- to 14.54-fold more sensitive than comparator assays based on the WHO International Reference Standard. The enhanced sensitivity was also demonstrated with 27 HBV seroconversion panels, detecting more panel members (191 of 364) vs. the ARCHITECT® Qual I (144), Qual II (160) and PRISM® (148) HBsAg assays. Further, the assay detected 7 of 12 HBV DNA positive/HBsAg negative samples, and detected all evaluated mutants and genotypes with higher sensitivity than the comparator assays. The improvement in sensitivity did not diminish assay specificity, attaining 100% (95% CI, 99.97-100%) on 10,633 blood donors. CONCLUSIONS: An Abbott ARCHITECT® HBsAg assay with clinical performance approaching that of mini-pool NAT (approximately 100 copies/ml was developed. The assay has superior HBsAg mutant and genotype detection and specificity, all of which are important for the diagnosis and management of HBV infection.
Authors: Johanna Mitterreiter; Heinrich Scheiblauer; Sarah Fiedler; Julia Kreß Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2022-01-13 Impact factor: 1.513
Authors: Mary C Kuhns; Vera Holzmayer; Mark Anderson; Anne L McNamara; Silvia Sauleda; Dora Mbanya; Pham T Duong; Nguyen T T Dung; Gavin A Cloherty Journal: Viruses Date: 2021-10-13 Impact factor: 5.048